MCID: BRS049
MIFTS: 44

Breast Carcinoma in Situ malady

Genetic diseases, Cancer diseases, Rare diseases, Reproductive diseases categories

Aliases & Classifications for Breast Carcinoma in Situ

About this section

Breast Carcinoma in Situ, Aliases & Descriptions:

Name: Breast Carcinoma in Situ 9
Non-Infiltrating Carcinoma of Breast 9
 
Carcinoma in Situ of Breast 9
Stage 0 Breast Carcinoma 60


Classifications:



External Ids:

Disease Ontology9 DOID:8791
ICD9CM27 233.0
NCIt38 C3641
ICD1025 D05

Summaries for Breast Carcinoma in Situ

About this section


MalaCards based summary: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is VEGFC (vascular endothelial growth factor C), and among its related pathways are Fanconi anemia pathway and Homologous Recombination Repair. The compounds topotecan and crcs have been mentioned in the context of this disorder. Affiliated tissues include breast and testes, and related mouse phenotypes are no phenotypic analysis and limbs/digits/tail.

Related Diseases for Breast Carcinoma in Situ

About this section

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Breast Benign Neoplasm
breast carcinoma in situ Familial Breast Cancer
Chek2-Related Susceptibility to Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Hereditary Breast Cancer

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 84)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer31.0BRCA2, BRCA1
2ductal carcinoma in situ29.9TP53, BRCA2, BRCA1, ERBB2, CDH1
3hereditary breast ovarian cancer10.5BRCA2
4chordoma10.4KRT19
5lobular neoplasia10.4
6nodular goiter10.3VEGFC, KRT19
7thyroid carcinoma, follicular10.3KRT19, VEGFC
8thyroid carcinoma, papillary10.3VEGFC, MET
9poland syndrome10.2
10brca1 and brca2 hereditary breast and ovarian cancer10.2BRCA2, BRCA1
11cystadenoma10.2BRCA1, VEGFC
12fallopian tube cancer10.2BRCA2, BRCA1
13peritoneal carcinoma10.2BRCA2, BRCA1
14bilateral breast cancer10.2BRCA2, BRCA1
15lynch syndrome10.2BRCA1, BRCA2
16tongue cancer10.2CDH1, VEGFC
17female breast carcinoma10.2
18breast apocrine carcinoma in situ10.2
19comedo carcinoma10.2
20hypoxia10.2
21dysgerminoma10.2BRCA2, BRCA1
22microinvasive gastric cancer10.2VEGFC, CDH1
23uveal melanoma10.2VEGFC, MET
24cowden disease10.2BRCA2, BRCA1
25gynecomastia10.2BRCA1, BRCA2
26laryngeal carcinoma10.2TP53, VEGFC
27bloom syndrome10.2BRCA1, BRCA2
28tongue squamous cell carcinoma10.2CDH1, KRT19
29neuroendocrine tumor10.1CDH1, KRT19
30nasopharynx carcinoma10.1TP53, CDH1
31aplastic anemia10.1BRCA1, BRCA2
32biliary tract neoplasm10.1MET, ERBB2
33lung benign neoplasm10.1KRT19, MET, TP53
34renal clear cell carcinoma10.1MET, CDH1
35breast fibroadenoma10.1VEGFC, ERBB2
36cervical cancer, somatic10.1VEGFC, TP53, KRT19
37sarcoma, synovial10.1CDH1, KRT19, MET
38follicular adenoma10.1MET, KRT19, CDH1
39mesothelioma, somatic10.0CDH1, MET
40fanconi anemia, complementation group a10.0BRCA1, BRCA2
41malignant mixed mullerian tumor10.0TP53, ERBB2
42esophageal cancer10.0VEGFC, TP53
43li-fraumeni syndrome10.0BRCA1, BRCA2, TP53
44bladder transitional cell carcinoma10.0CDH1, TP53, VEGFC
45xeroderma pigmentosum, variant type10.0BRCA1, TP53
46mesothelioma10.0KRT19, MET
47ataxia-telangiectasia10.0BRCA1, BRCA2, TP53
48thyroid cancer, anaplastic10.0TP53, MET, CDH1
49nasopharyngeal carcinoma10.0VEGFC, TP53, CDH1
50renal cell carcinoma10.0TP53, MET, CDH1

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Symptoms for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section

MalaCards organs/tissues related to Breast Carcinoma in Situ:

31
Breast, Testes

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

35 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.4CDH1, KRT19, MET, TP53
2MP:00053718.4TP53, BRCA2, BRCA1, MET, ERBB2
3MP:00053888.3TP53, BRCA1, MET, ERBB2
4MP:00053868.2ERBB2, MET, BRCA1, BRCA2, TP53
5MP:00053908.1TP53, BRCA2, BRCA1, ERBB2, KRT19
6MP:00036317.7TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
7MP:00053817.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
8MP:00053807.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
9MP:00028737.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
10MP:00053857.5VEGFC, TP53, BRCA1, MET, ERBB2, KRT19
11MP:00053787.3TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
12MP:00053877.3VEGFC, SDC1, TP53, BRCA2, BRCA1, MET
13MP:00107717.0SDC1, TP53, BRCA2, BRCA1, ERBB2, KRT19
14MP:00053897.0SDC1, TP53, BRCA2, BRCA1, ERBB2, KRT19
15MP:00053766.8VEGFC, SDC1, TP53, BRCA2, BRCA1, MET
16MP:00020066.7CDH1, SDC1, TP53, BRCA2, BRCA1, MET
17MP:00053796.7SDC1, TP53, BRCA2, BRCA1, MET, ERBB2
18MP:00053846.7SDC1, TP53, BRCA2, BRCA1, MET, ERBB2
19MP:00107686.4VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Publications for Breast Carcinoma in Situ

About this section

Articles related to Breast Carcinoma in Situ:

(show all 40)
idTitleAuthorsYear
1
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. (22595929)
2012
2
Differences in breast carcinoma in situ between menopausal and premenopausal women. (21617240)
2011
3
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. (21149333)
2010
4
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. (20565829)
2010
5
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? (19896281)
2010
6
Prevalence of breast carcinoma in situ in the United States. (19706857)
2009
7
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. (18665169)
2008
8
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
9
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. (17244359)
2007
10
Cigarette smoking and risk of breast carcinoma in situ. (17700252)
2007
11
Oral contraceptive use and risk of breast carcinoma in situ. (18006914)
2007
12
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. (17063272)
2007
13
Quality of life for women diagnosed with breast carcinoma in situ. (17050872)
2006
14
Molecular classification of breast carcinoma in situ. (17375183)
2006
15
Oral contraceptive use and risk of breast carcinoma in situ (United States). (17006721)
2006
16
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. (15540225)
2005
17
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. (15841074)
2005
18
Impact of reproductive factors and lactation on breast carcinoma in situ risk. (15054874)
2004
19
Proliferative lesions of the breast: carcinoma in situ. (15022899)
2003
20
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. (14659121)
2003
21
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. (12611452)
2003
22
Oral contraceptives and the risk of ductal breast carcinoma in situ. (14572155)
2003
23
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. (12670886)
2003
24
Lifetime recreational exercise activity and risk of breast carcinoma in situ. (14601085)
2003
25
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. (12118344)
2002
26
Breast carcinoma in situ: risk factors and screening patterns. (11734598)
2001
27
p53 mutations and expression in breast carcinoma in situ. (10623666)
2000
28
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. (9622698)
1998
29
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. (9071907)
1997
30
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. (8692711)
1996
31
Biological heterogeneity of breast carcinoma in situ. (8651598)
1996
32
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. (7654052)
1995
33
Breast carcinoma in situ. (20169700)
1992
34
Breast carcinoma-in-situ: an emerging problem in Singapore. (1329232)
1992
35
Receptors for estrogen and progesterone in breast carcinoma in situ. (1295456)
1992
36
Ten-year follow-up of breast carcinoma in situ in Connecticut. (1365682)
1992
37
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. (1677296)
1991
38
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. (1657650)
1991
39
Breast carcinoma in situ. (2535929)
1989
40
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. (2990246)
1985

Variations for Breast Carcinoma in Situ

About this section

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50)    (show all 54)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.7BRCA1, BRCA2
2
Show member pathways
9.7BRCA2, BRCA1
39.7CDH1, MET
49.7CDH1, MET
59.7CDH1, MET
69.4BRCA1, TP53
79.4BRCA1, TP53
89.4BRCA1, TP53
99.4BRCA1, TP53
109.4TP53, BRCA1
119.4TP53, BRCA1
12
Show member pathways
ATM Signaling Pathway36
9.4TP53, BRCA1
139.4TP53, CDH1
14
Show member pathways
9.4CDH1, MET, VEGFC
159.3KRT19, TP53
169.3MET, SDC1
179.3VEGFC, MET, ERBB2
189.2CDH1, SDC1
199.2MET, ERBB2, CDH1
209.2MET, ERBB2, CDH1
21
Show member pathways
9.2MET, ERBB2, CDH1
22
Show member pathways
9.1TP53, BRCA2, BRCA1
239.1TP53, BRCA2, BRCA1
24
Show member pathways
9.1TP53, BRCA2, BRCA1
25
Show member pathways
9.1TP53, BRCA2, BRCA1
26
Show member pathways
9.1CDH1, MET, TP53
27
Show member pathways
9.0ERBB2, MET, TP53
289.0ERBB2, MET, TP53
29
Show member pathways
9.0TP53, BRCA2, ERBB2
308.9CDH1, ERBB2, TP53
31
Show member pathways
Signal transduction PTEN pathway58
8.9TP53, ERBB2, CDH1
32
Show member pathways
8.8CDH1, ERBB2, MET, VEGFC
33
Show member pathways
8.8VEGFC, MET, ERBB2, CDH1
348.8MET, BRCA1, TP53, VEGFC
35
Show member pathways
8.7ERBB2, MET, TP53, VEGFC
36
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
37
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
388.6CDH1, BRCA1, BRCA2, TP53
398.6TP53, BRCA1, MET, ERBB2
40
Show member pathways
Wnt Signaling Pathway NetPath36
8.6CDH1, TP53, SDC1
418.5ERBB2, BRCA1, BRCA2, TP53
42
Show member pathways
Integrin-mediated cell adhesion36
Focal Adhesion36
8.5VEGFC, SDC1, MET, ERBB2
438.2ERBB2, MET, TP53, SDC1
44
Show member pathways
Development EGFR signaling via PIP358
Development PDGF signaling via MAPK cascades58
Apoptosis and survival Anti apoptotic action of membrane bound ESR158
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases58
Development Neurotrophin family signaling58
Apoptosis and survival NGF signaling pathway58
Apoptosis and survival Role of CDK5 in neuronal death and survival58
8.2SDC1, TP53, MET, ERBB2
45
Show member pathways
7.9VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
467.8VEGFC, TP53, BRCA2, MET, ERBB2, CDH1
47
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, ERBB2, CDH1
48
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, ERBB2, CDH1
49
Show member pathways
Signaling Pathways in Glioblastoma36
7.7CDH1, ERBB2, MET, BRCA1, BRCA2, TP53

Compounds for genes affiliated with Breast Carcinoma in Situ

About this section

Compounds related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50)    (show all 108)
idCompoundScoreTop Affiliating Genes
1topotecan43 1211.4BRCA1
2crcs439.4CDH1, MET, TP53
3o6-methylguanine439.4CDH1, BRCA2, TP53
4methylmethanesulfonate439.4TP53, BRCA2, BRCA1
55-methylcytosine43 2410.3CDH1, BRCA1, TP53
64-hydroxytamoxifen439.3ERBB2, BRCA1, BRCA2
7leptomycin b43 5910.2TP53, BRCA1, CDH1
8gefitinib43 49 1211.2CDH1, ERBB2, MET
9suberoylanilide hydroxamic acid439.1CDH1, ERBB2, TP53
10oxaliplatin43 49 1211.1ERBB2, BRCA1, TP53
11p003439.1CDH1, KRT19, BRCA1, BRCA2
12folate439.1BRCA2, BRCA1, ERBB2, CDH1
13agar439.1BRCA1, MET, ERBB2, CDH1
14methotrexate49 43 1211.0BRCA2, BRCA1, ERBB2, CDH1
15indole-3-carbinol439.0TP53, BRCA2, BRCA1, CDH1
16bortezomib43 49 1211.0TP53, BRCA1, ERBB2
17phosphotyrosine439.0BRCA1, MET, ERBB2, CDH1
18geldanamycin43 49 59 1211.9TP53, MET, ERBB2, CDH1
19resveratrol43 59 24 1211.9TP53, BRCA2, BRCA1, ERBB2
20irinotecan43 49 1210.9CDH1, ERBB2, TP53
21matrigel438.9VEGFC, BRCA2, MET, KRT19, CDH1
22thymidylate438.8TP53, BRCA1, ERBB2, CDH1
235fluorouracil438.8CDH1, ERBB2, BRCA1, TP53
24heparin43 28 24 1211.8VEGFC, BRCA1, MET, ERBB2, CDH1
25bleomycin43 129.8BRCA1, BRCA2, TP53
26estradiol43 24 1210.7VEGFC, BRCA2, BRCA1, KRT19
27genistein43 28 59 2 24 1213.7CDH1, ERBB2, MET, BRCA1, BRCA2
28oligonucleotide438.7VEGFC, TP53, BRCA2, BRCA1, MET
29proline438.6TP53, BRCA2, BRCA1, MET, CDH1
30ly294002438.6VEGFC, TP53, MET, ERBB2, CDH1
31steroid438.6BRCA2, BRCA1, MET, ERBB2, KRT19
32docetaxel43 49 59 1211.5TP53, BRCA2, BRCA1, ERBB2, CDH1
33doxorubicin43 49 1210.5TP53, BRCA1, MET, ERBB2, CDH1
34etoposide43 49 59 1211.5CDH1, ERBB2, BRCA1, BRCA2, TP53
35tamoxifen43 49 28 1211.5TP53, BRCA2, BRCA1, ERBB2, CDH1
36phosphatidylinositol438.5VEGFC, BRCA2, BRCA1, MET, ERBB2, CDH1
37thymidine43 249.3VEGFC, TP53, BRCA2, BRCA1, MET, KRT19
38p002438.3BRCA2, BRCA1, MET, ERBB2, KRT19, CDH1
39cycloheximide438.1TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
40tyrosine438.0VEGFC, BRCA1, MET, ERBB2, KRT19, CDH1
41paclitaxel43 49 1210.0TP53, BRCA2, BRCA1, ERBB2, KRT19, CDH1
42testosterone43 59 24 1211.0VEGFC, BRCA2, BRCA1, MET, ERBB2, KRT19
43retinoic acid43 248.9VEGFC, TP53, BRCA2, BRCA1, MET, KRT19
44serine437.8CDH1, KRT19, ERBB2, MET, BRCA1, TP53
45vegf437.7VEGFC, TP53, BRCA1, MET, ERBB2, KRT19
46adriamycin437.7CDH1, TP53, BRCA2, BRCA1, MET, ERBB2
47cisplatin43 49 59 1210.7TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
48paraffin437.4VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
49progesterone43 28 59 24 1211.4VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
50estrogen437.3VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1focal adhesionGO:00059258.5SDC1, BRCA1, CDH1
2protein complexGO:00432348.1BRCA1, BRCA2, TP53, SDC1
3cytoplasmGO:00057377.3CDH1, ERBB2, BRCA1, BRCA2, TP53, SDC1

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:00716819.9CDH1, BRCA1
2response to X-rayGO:00101659.7BRCA2, TP53
3positive regulation of cell cycle arrestGO:00711589.7BRCA1, TP53
4cell agingGO:00075699.7TP53, BRCA2
5response to gamma radiationGO:00103329.6BRCA2, TP53
6intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:00427719.6BRCA2, TP53
7response to estrogenGO:00436279.5BRCA1, KRT19
8positive regulation of epithelial cell proliferationGO:00506799.5ERBB2, VEGFC
9double-strand break repair via homologous recombinationGO:00007249.4BRCA1, BRCA2
10DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.4BRCA1, BRCA2, TP53
11double-strand break repairGO:00063029.3TP53, BRCA2, BRCA1
12wound healingGO:00420609.1ERBB2, SDC1
13cell proliferationGO:00082839.1ERBB2, MET, TP53
14positive regulation of transcription, DNA-templatedGO:00458938.9TP53, BRCA2, BRCA1, CDH1

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:00020209.5BRCA2, TP53
2glycoprotein bindingGO:00019488.9CDH1, SDC1
3protein phosphatase bindingGO:00199038.5CDH1, ERBB2, MET, TP53
4protein bindingGO:00055156.0VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Products for genes affiliated with Breast Carcinoma in Situ

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Breast Carcinoma in Situ

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet